---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014203"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:22:13.453005+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement

## Summary
- Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).
- Cash, cash equivalents and investments $98.3M as of Sept 30, 2024, vs $9.8M at Dec 31, 2023.
- Closed private placement in Aug 2024 yielding approximately $100M gross proceeds.
- Phase 3 LEVEL study for levosimendan ongoing: 52 investigative sites initiated, enrolling patients.
- Cash runway projected through end of 2027 based on current operating plan.

## SEC filing metadata
- accession: 0001654954-24-014203
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424014203/0001654954-24-014203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424014203/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014203
- JSON: https://secwatch.observer/filing/0001654954-24-014203.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.